(Treffer aus pharmind, Nr. 02, Seite 164 (2022))
Nakad R | Fischer B
Safety profiles of EU-approved COVID-19 vaccines / What we know so far – Part 2*Part 1 of this article see Pharm. Ind. 2021;83(12):1563–1572. · Nakad R, Fischer B · SCRATCH Pharmacovigilance GmbH & Co. KG, Butzbach
In Apr. 2021, the EMA began to analyse the occurrence of capillary leak syndrome after vaccination with Vaxzevria. Capillary leak syndrome (CLS) is a rare disorder with massive, disseminated leakage of fluid from the small blood vessels and capillaries into the surrounding tissue leading to a rapid drop of blood pressure and tissue swelling accompanied by haemoconcentration and hypalbuminaemia [ 77 ], possibly manifesting in a life-threatening condition with hypovolemic shock and multiple organ failure [ 78 ]. 5 cases had been reported at that time to the European safety database EudraVigilance with 34 Mio. doses of Vaxzevria administered [ 53 ]. ...